Enzolytics, Inc. (OTCMKTS:ENZC – Get Free Report) was the recipient of a large drop in short interest in February. As of February 13th, there was short interest totaling 412,513 shares, a drop of 39.1% from the January 29th total of 677,542 shares. Based on an average daily trading volume, of 14,177,742 shares, the days-to-cover ratio is presently 0.0 days. Based on an average daily trading volume, of 14,177,742 shares, the days-to-cover ratio is presently 0.0 days.
Enzolytics Trading Down 16.7%
OTCMKTS:ENZC opened at $0.00 on Friday. Enzolytics has a 12 month low of $0.00 and a 12 month high of $0.00.
About Enzolytics
Enzolytics, Inc is a clinical-stage biotechnology company focused on advancing immunotherapeutic treatments for infectious diseases. Its core platform employs proprietary peptide and monoclonal antibody technologies designed to target and neutralize viral pathogens. The company’s lead candidate, Investigator Therapeutic Vaccine-1 (ITV-1), is a 72-amino-acid peptide engineered to bind multiple HIV-1 strains and support immune response in affected individuals.
In addition to its HIV program, Enzolytics has leveraged its antibody discovery engine to develop broadly neutralizing monoclonal antibodies against coronaviruses, including SARS-CoV-2.
Featured Articles
- Five stocks we like better than Enzolytics
- “Fed Proof” Your Bank Account with THESE 4 Simple Steps
- Unlocked: Elon Musk’s Next Big IPO
- Buffett, Gates and Bezos Quietly Dumping Stocks—Here’s Why
- Read this or regret it forever
- Silver paying 20% dividend. Plus 68% share gains
Receive News & Ratings for Enzolytics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enzolytics and related companies with MarketBeat.com's FREE daily email newsletter.
